ACP
INDP icon

Acuta Capital Partners’s Indaptus Therapeutics INDP Stock Holding History

Acuta Capital Partners’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,323
Closed -$13M – 39
2018
Q2 		$13M Buy
1,323
+107
+9% +$1.19M 2.32% 11
2018
Q1 		$17.2M Hold
1,216
– – 2.81% 11
2017
Q4 		$14M Hold
1,216
– – 2.65% 13
2017
Q3 		$24.4M Buy
1,216
+1,037
+579% +$15M 4.37% 7
2017
Q2 		$2.28M Buy
+179
New +$2.17M 0.64% 30

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Acuta Capital Partners's INDP Position: Q3 2018 in Review

Acuta Capital Partners sold out of Indaptus Therapeutics (INDP) in Q3 2018, closing a stake of 1,323 shares — an estimated $13M sold.

Acuta Capital Partners first reported a position in INDP in Q2 2017 and held it in 5 quarters. The position peaked at $24.4M in Q3 2017. 25 funds tracked by Wall St. Rank hold INDP as of Q3 2018.

  • Acuta Capital Partners reported no remaining Indaptus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Acuta Capital Partners sold 1,323 Indaptus Therapeutics shares in Q3 2018, an estimated $13M.
  • Acuta Capital Partners first reported a position in Indaptus Therapeutics in Q2 2017 and held it in 5 quarters.
  • Acuta Capital Partners's Indaptus Therapeutics position peaked at $24.4M in Q3 2017.
  • 25 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2018.

Based on Acuta Capital Partners's 13F filing for Q3 2018, filed 7 Nov 2018.